Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $125.71.
A number of equities analysts recently commented on LNTH shares. Truist Financial reiterated a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Redburn Atlantic started coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target for the company. JMP Securities reduced their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. Finally, StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st.
View Our Latest Stock Report on LNTH
Institutional Investors Weigh In On Lantheus
Lantheus Price Performance
Shares of NASDAQ LNTH opened at $89.27 on Monday. The stock has a market capitalization of $6.21 billion, a price-to-earnings ratio of 14.85 and a beta of 0.51. The business has a 50-day moving average of $101.76 and a 200-day moving average of $97.04. Lantheus has a fifty-two week low of $50.20 and a fifty-two week high of $126.89.
About Lantheus
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
See Also
- Five stocks we like better than Lantheus
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- 3 Penny Stocks Ready to Break Out in 2025
- How to invest in marijuana stocks in 7 stepsĀ
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.